Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VEGF antagonists.

J Hasan1, G C Jayson

  • 1Department of Medical Oncology, Cancer Research Campaign Dept. Medical Oncology, Christie Hospital, Wilmslow Road, Withington, Manchester M20 4BX, UK.

Expert Opinion on Biological Therapy
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bactericidal efficiency of micro- and nanostructured surfaces: a critical perspective.

RSC advances·2022
Same author

Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers.

ESMO open·2022
Same author

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.

ESMO open·2021
Same author

Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2020
Same author

Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2020
Same author

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.

European journal of cancer (Oxford, England : 1990)·2019
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Vascular endothelial growth factor (VEGF) antagonists, including monoclonal antibodies and receptor tyrosine kinase inhibitors, show promise in treating various cancers by inhibiting blood vessel formation. Further research is needed to optimize their use in combination therapies and non-malignant conditions.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth.
  • Vascular Endothelial Growth Factor (VEGF) is a primary driver of angiogenesis.
  • Targeting VEGF and its receptors (VEGFRs) is a key strategy in cancer therapy.

Purpose of the Study:

  • To review current strategies for developing VEGF/VEGFR antagonists.
  • To evaluate the efficacy and safety of these antagonists in preclinical and clinical settings.
  • To explore the potential applications of VEGF antagonists in both malignant and non-malignant diseases.

Main Methods:

  • Review of gene therapy techniques (antisense oligonucleotides, soluble VEGFRs, ribozymes).
  • Analysis of receptor tyrosine kinase (RTK) inhibitors and monoclonal antibodies (mAbs) against VEGF or VEGFR.

Related Experiment Videos

  • Examination of early-phase clinical trial data for advanced cancers.

    • Main Results:

    • Monoclonal anti-VEGF antibodies and RTK inhibitors demonstrate broad antitumor activity.
    • RTK inhibitors offer the advantage of oral administration.
    • Early trials indicate VEGF antagonists are generally well-tolerated, with potential vascular toxicities like hemorrhage and thromboembolic events.

    Conclusions:

    • VEGF antagonists, particularly mAbs and RTK inhibitors, show significant promise for treating various cancers, including breast, colorectal, and Kaposi's sarcoma.
    • Combination therapies with chemotherapy require further validation in Phase III trials.
    • Potential applications extend to non-malignant conditions, necessitating the identification of optimal biological endpoints for clinical trials.